(-)-[3S,4R]-6-cyano-4-(N-ethylsulfonyl-N-methylamino)-3-hydroxy-2,2-dimethyl-chromane | 163163-25-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: (-)-[3S,4R]-6-cyano-4-(N-ethylsulfonyl-N-methylamino)-3-hydroxy-2,2-dimethyl-chromane
• 英文别名: 3S,4R-293B；(+)-Chromanol 2393B；N-[(3S,4R)-6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-N-methylethanesulfonamide
• CAS: 163163-25-5
• 化学式: C₁₅H₂₀N₂O₄S
• 分子量: 324.401
• InChiKey: HVSJHHXUORMCGK-KGLIPLIRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  99
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  N-methyl-N-trimethylsilyl-ethanesulfonamide 、 6-cyano-2,2-dimethylchromene-3,4-epoxide 在 四丁基氟化铵 作用下， 生成 (-)-[3S,4R]-6-cyano-4-(N-ethylsulfonyl-N-methylamino)-3-hydroxy-2,2-dimethyl-chromane
  参考文献：
  名称：

  Yang; Scherz; Bahinski, Journal of Pharmacology and Experimental Therapeutics, 2000, vol. 294, # 3, p. 955 - 962

  摘要：

  DOI：

文献信息

• GPBP-1 inhibition and its therapeutic use
  申请人：Flbrostatin S.L.

  公开号：US20140005134A1

  公开（公告）日：2014-01-02

  The present invention provides compositions including anti-tumor agents and inhibitors of Goodpasture antigen binding protein, p21, and ABCC7, and their use in treating cancer.

  本发明提供了包括抗肿瘤药物和Goodpasture抗原结合蛋白、p21和ABCC7的抑制剂在内的组合物，并且这些组合物可用于治疗癌症。
• Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity
  申请人：LIEBER INSTITUTE FOR BRAIN DEVELOPMENT

  公开号：US11221329B2

  公开（公告）日：2022-01-11

  Provided are methods for treating and/or reducing the symptoms of a neurological or neurodevelopmental disease or disorder characterized by ectopic expression of certain ion channels, in particular, the Nav1.8 subtype SCN10a sodium channel, or the KCNQ1 potassium channel, in neuronal cells of the central nervous system (CNS) of a subject by administering to a subject in need an antagonist of one or both of these ion channels, and in particular, an antagonist of SCN10a, to block, reduce, or suppress the aberrant CNS neuronal ion channel expression and/or activity and normalize behavioral and cognitive defects associated with the neurological and neurodevelopmental disease or disorder, so as to treat and/or reduce the symptoms of the neurological or neurodevelopmental disease or disorder. Examples of such diseases or disorders that may be treated by the described methods include, for example, Pitt-Hopkins Syndrome (PTHS), autism, autism spectrum disorder, schizophrenia, 18q syndrome and the like.

  本发明提供了用于治疗和/或减轻神经或神经发育疾病或紊乱症状的方法，该疾病或紊乱的特征是某些离子通道的异位表达，特别是 Nav1.8 亚型 SCN10a 钠通道或 KCNQ1 钾通道在中枢神经系统（CNS）神经细胞中的异位表达。8亚型SCN10a钠通道或KCNQ1钾通道的方法，该方法通过向有需要的受试者施用一种或两种这些离子通道的拮抗剂，特别是SCN10a的拮抗剂，以阻断、减少或抑制异常的中枢神经系统（CNS）离子通道、或抑制异常的中枢神经系统神经元离子通道表达和/或活性，使与神经系统和神经发育疾病或紊乱相关的行为和认知缺陷正常化，从而治疗和/或减轻神经系统或神经发育疾病或紊乱的症状。可通过所述方法治疗的此类疾病或紊乱的例子包括皮特-霍普金斯综合征（PTHS）、自闭症、自闭症谱系障碍、精神分裂症、18q 综合征等。
• Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP0807629B1

  公开（公告）日：2004-03-03
• VERWENDUNG VON INHIBITOREN DES KQT1-KANALS ZUR HERSTELLUNG EINES MEDIKAMENTS ZUR BEHANDLUNG VON KRANKHEITEN, DIE DURCH HELMINTHEN UND EKTOPARASITEN HERVORGERUFEN WERDEN
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：EP1140042B1

  公开（公告）日：2008-03-26
• CELLS AND ASSAYS FOR USE IN DETECTING LONG QT SYNDROME
  申请人：Conklin Bruce R.

  公开号：US20090227469A1

  公开（公告）日：2009-09-10

  The present disclosure provides induced pluripotent stem (iPS) cells, and induced multipotent stem (iMS) cells, and progeny thereof, which cells include a gene encoding a polypeptide that regulates the QT interval. The present disclosure further provides panels of cardiomyocytes suitable for use in screening compounds for an effect on the QT interval. The cells and panels of cells can be used in a variety of applications, which are also provided.